JP2003510329A5 - - Google Patents

Download PDF

Info

Publication number
JP2003510329A5
JP2003510329A5 JP2001526545A JP2001526545A JP2003510329A5 JP 2003510329 A5 JP2003510329 A5 JP 2003510329A5 JP 2001526545 A JP2001526545 A JP 2001526545A JP 2001526545 A JP2001526545 A JP 2001526545A JP 2003510329 A5 JP2003510329 A5 JP 2003510329A5
Authority
JP
Japan
Prior art keywords
acid
rapamycin
carbons
silyl ether
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001526545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003510329A (ja
JP4289813B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/026445 external-priority patent/WO2001023395A2/en
Publication of JP2003510329A publication Critical patent/JP2003510329A/ja
Publication of JP2003510329A5 publication Critical patent/JP2003510329A5/ja
Application granted granted Critical
Publication of JP4289813B2 publication Critical patent/JP4289813B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001526545A 1999-09-29 2000-09-27 ラパマイシン誘導体のレギオ選択的な合成 Expired - Fee Related JP4289813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40883099A 1999-09-29 1999-09-29
US09/408,830 1999-09-29
PCT/US2000/026445 WO2001023395A2 (en) 1999-09-29 2000-09-27 Regioselective synthesis of rapamycin derivatives

Publications (3)

Publication Number Publication Date
JP2003510329A JP2003510329A (ja) 2003-03-18
JP2003510329A5 true JP2003510329A5 (enExample) 2008-02-21
JP4289813B2 JP4289813B2 (ja) 2009-07-01

Family

ID=23617953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001526545A Expired - Fee Related JP4289813B2 (ja) 1999-09-29 2000-09-27 ラパマイシン誘導体のレギオ選択的な合成

Country Status (24)

Country Link
EP (1) EP1216251B1 (enExample)
JP (1) JP4289813B2 (enExample)
KR (1) KR100754236B1 (enExample)
CN (1) CN1176925C (enExample)
AR (1) AR029181A1 (enExample)
AT (1) ATE233269T1 (enExample)
AU (1) AU782234B2 (enExample)
BR (1) BR0014433A (enExample)
CA (1) CA2385461C (enExample)
CZ (1) CZ300368B6 (enExample)
DE (1) DE60001510T2 (enExample)
DK (1) DK1216251T3 (enExample)
EA (1) EA004331B1 (enExample)
ES (1) ES2189768T3 (enExample)
HK (1) HK1044774B (enExample)
HU (1) HUP0202609A3 (enExample)
IL (2) IL148542A0 (enExample)
MX (1) MXPA02003243A (enExample)
NO (1) NO20021360L (enExample)
NZ (1) NZ517644A (enExample)
PL (1) PL200899B1 (enExample)
TW (1) TWI256395B (enExample)
WO (1) WO2001023395A2 (enExample)
ZA (1) ZA200201918B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
JP2007532650A (ja) 2004-04-14 2007-11-15 ワイス プロリンcci−779(2,2−ビス(ヒドロキシメチル)プロピオン酸とのプロリン−ラパマイシン42−エステル)ならびに細菌リパーゼを使用するプロリンcci−779およびcci−779の二段階酵素的合成
CN1942476A (zh) 2004-04-14 2007-04-04 惠氏公司 纳巴霉素42-酯衍生物的区位特异合成
CN1993368A (zh) 2004-08-10 2007-07-04 惠氏公司 Cci-779衍生物和其制备方法
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
JP2008530090A (ja) 2005-02-09 2008-08-07 ワイス Cci−779多形及びその使用
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
EP2528906A2 (en) * 2010-01-28 2012-12-05 Fresenius Kabi Oncology Ltd Process for the preparation of temsirolimus and its intermediates
CN102020662B (zh) 2011-01-07 2013-02-13 天津市炜杰科技有限公司 一种驮瑞塞尔制备方法
MX2013011412A (es) * 2011-04-01 2014-04-30 Sandoz Ag Acilacion regioselectiva de rapamicina en la posicion c-42.
CN103421023B (zh) * 2013-07-30 2015-09-23 福建省微生物研究所 一种替西罗莫司的合成工艺
CN104086564B (zh) * 2014-07-30 2019-02-05 江苏奥赛康药业股份有限公司 一种高纯度坦罗莫司的制备方法
CN106146536B (zh) * 2015-04-25 2019-07-26 山东新时代药业有限公司 一种依维莫司的制备方法
CN109562187B (zh) * 2016-03-14 2022-05-17 威斯康星校友研究基金会 具有增强的抗癌功效的低聚乳酸缀合物和胶束
CN107561170B (zh) * 2016-07-02 2021-07-30 山东新时代药业有限公司 一种坦西莫司中间体的分析检测方法
CN108948045A (zh) * 2017-05-20 2018-12-07 鲁南制药集团股份有限公司 一种替西罗莫司的制备方法
CN108948046B (zh) * 2017-05-20 2020-11-10 鲁南制药集团股份有限公司 一种替西罗莫司的中间体及其制备方法
CN109206441B (zh) * 2017-06-30 2022-05-20 正大天晴药业集团股份有限公司 一种依维莫司的纯化方法
CN109776570A (zh) * 2017-11-14 2019-05-21 上海医药工业研究院 一种依维莫司中间体、其制备方法及其应用
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
CN109369679A (zh) * 2018-12-24 2019-02-22 江苏卓和药业有限公司 一种雷帕霉素的精制方法
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途
CN113372359A (zh) * 2020-03-10 2021-09-10 鲁南制药集团股份有限公司 一种坦西莫司的制备方法
CN114106014B (zh) * 2020-08-27 2024-03-15 鲁南制药集团股份有限公司 一种依维莫司的制备方法
CN115028658A (zh) * 2022-07-06 2022-09-09 国药集团川抗制药有限公司 雷帕霉素硅醇酯及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines

Similar Documents

Publication Publication Date Title
JP2003510329A5 (enExample)
JP4289813B2 (ja) ラパマイシン誘導体のレギオ選択的な合成
US6277983B1 (en) Regioselective synthesis of rapamycin derivatives
JPH0578377A (ja) ラパマイシンのシリルエーテル類
CA3028453C (en) Intermediates for the preparation of analogs of halichondrin b
CN1124276C (zh) 雷帕霉素衍生物
JP2018150331A5 (enExample)
JP5117390B2 (ja) メイタンシノールの調製法
JP2015517402A5 (enExample)
KR950703567A (ko) O-알킬화된 라파미신 유도체 및 면역 억제제로서의 용도 (o-alkylated rapamycin derivatives and their use, particularly as immuno-suppressants)
KR970702283A (ko) 라파마이신 하이드록시에스테르, 이의 제조방법 및 이를 함유하는 약제학적 조성물(Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them)
WO2012048058A3 (en) Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
JP2008542214A5 (enExample)
JP2019516720A5 (enExample)
JP2006528667A5 (enExample)
JP2005522515A5 (enExample)
JP6167936B2 (ja) 環状シラザン化合物の製造方法
JP2008053657A5 (enExample)
DE102007055341A1 (de) Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
ATE535538T1 (de) Verfahren zur herstellung von guggulsteronen und guggulsterol
JP2010530379A5 (enExample)
KR830006306A (ko) α-치환 우레이도 벤질 페니실린 유도체의 제조방법
CA2584052A1 (en) Process for the esterification of a carbothioic acid
JP2001519332A (ja) カルバペネム中間体の合成方法、および製造された化合物